» Articles » PMID: 27246683

Analytical Characterization of Cyclodextrins: History, Official Methods and Recommended New Techniques

Overview
Specialty Chemistry
Date 2016 Jun 2
PMID 27246683
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The main goal of this review is to provide a comprehensive overview on the methods used for analysis of cyclodextrins (CDs) and CD-derivatives. The paper intends to act as a guide for the readers in looking around the classical and modern instrumental analytical methods suitable for identification, characterization and determination of CDs themselves, CDs in finished products or even in biological samples. At present, in the European and United States Pharmacopoeias, the three parent CDs and two synthetic derivatives, namely the (2-hydroxypropyl)-beta-CD and sulfobutylether-beta-CD Na salt are official. Besides these modified CDs, two other derivatives are approved as excipients in human pharmaceutical products: the (2-hydroxypropyl)-gamma-CD and the randomly methylated-beta-CD. Although most of the official analysis methods in the pharmacopoeias have been well used for decades, new aspects of the functional excipient CD characterization suggest a need to revisit compendial methods. Comparison of strengths and weaknesses of current official methods with new improved techniques intends to help analysts to decide on changing traditional analytical methods with improved new ones. This review also deals with the analytical aspects of the first single isomer CD derivative approved as a drug active (Sugammadex/Bridion) as well as analytical considerations of using CDs themselves as active pharmaceutical ingredients. Stability-indicating instrumental methods suitable to adequately follow chemical- and enzymatic degradation of CDs will also be discussed. Challenges in the determination of CDs in different biological matrices will be illustrated on real pharmaco- and toxicokinetic studies of CD-enabled drug formulations.

Citing Articles

Biopharmaceutical Characterization and Stability of Nabumetone-Cyclodextrins Complexes Prepared by Grinding.

Klaric D, Soldin Z, Vincze A, Szollath R, Balogh G, Jug M Pharmaceutics. 2025; 16(12.

PMID: 39771473 PMC: 11679744. DOI: 10.3390/pharmaceutics16121493.


Quorum quenching effect of cyclodextrins on the pyocyanin and pyoverdine production of Pseudomonas aeruginosa.

Fekete-Kertesz I, Berkl Z, Buda K, Fenyvesi E, Szente L, Molnar M Appl Microbiol Biotechnol. 2024; 108(1):271.

PMID: 38517512 PMC: 10959793. DOI: 10.1007/s00253-024-13104-7.


Cyclodextrin Inclusion Complexes for Improved Drug Bioavailability and Activity: Synthetic and Analytical Aspects.

Sarabia-Vallejo A, Caja M, Olives A, Martin M, Menendez J Pharmaceutics. 2023; 15(9).

PMID: 37765313 PMC: 10534465. DOI: 10.3390/pharmaceutics15092345.


Enantioseparation and molecular docking study of selected chiral pharmaceuticals on a commercialized phenylcarbamate-β-cyclodextrin column using polar organic mode.

Dobo M, Adam M, Fiser B, Papp L, Dombi G, Sekkoum K Sci Rep. 2023; 13(1):14778.

PMID: 37679395 PMC: 10485059. DOI: 10.1038/s41598-023-41941-5.


Cyclodextrin: A prospective nanocarrier for the delivery of antibacterial agents against bacteria that are resistant to antibiotics.

Saha P, Rajdoula Rafe M Heliyon. 2023; 9(9):e19287.

PMID: 37662769 PMC: 10472013. DOI: 10.1016/j.heliyon.2023.e19287.